Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX: PBT) covers the month of November 2011. The registrant is a foreign private issuer based in Australia. The filing serves as a notice under Section 708A(5) of the Corporations Act regarding a new issuance of securities and an application for quotation on the Australian Securities Exchange (ASX).
Key Financial Metrics and Capital Structure
- Securities Issued: 1,052,000 Ordinary Fully Paid Shares.
- Total Consideration: AUD$167,906.
- Implied Issue Price: Approximately AUD$0.16 per share (calculated from total consideration and share count).
- Purpose of Issue: To fund current clinical development, research programs, and working capital.
- Total Quoted Securities: 282,660,383 Ordinary Shares (including the new issue).
- Unquoted Securities: The company holds various unlisted options under different plans (e.g., 2004 ASX Plan, 2004 US ADS Plan) with exercise prices ranging from $Nil to US$5.00 per option.
Note: The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. It is a capital transaction announcement rather than a financial results report.
Material Changes
The primary material change is the increase in the company's share capital by 1,052,000 shares. These new shares rank pari passu with existing ordinary shares from the date of allotment (November 21, 2011). The total number of quoted ordinary shares increased to 282,660,383.
Outlook, Risks, and Management Commentary
Management indicates the capital raise is intended to support ongoing clinical development and research programs. The company has applied for quotation of the new shares on the ASX. The filing confirms compliance with Chapter 2M and Section 674 of the Corporations Act. No specific risks, contingencies, or unusual items beyond the standard capital issuance are detailed in this specific document.
Investor Verification Checklist
- Verify the exact per-share issue price and the identity of the investors who subscribed to the 1,052,000 shares.
- Confirm the current cash position and runway for clinical development following the AUD$167,906 raise.
- Review the terms and dilution impact of the various unlisted options (PBTAB, PBTAD, PBTAI, etc.) listed in the filing.
- Check for any subsequent filings regarding the status of the clinical programs funded by this capital.